

IN THE CLAIMS

1. (previously presented) A method of male contraception comprising the step of: administering to a non-sterile male subject a predetermined amount of a non-5 α -reducible androgen which is sufficient to render said male subject reversibly sterile for a predetermined period of time and which provides said male subject with blood levels of LH and FSH of 2.5 IU/L or less and testosterone of 10 nmol/liter or less and wherein said androgen is substantially the only sterilizing agent administered to said male subject for the purposes of contraception.

2. (previously presented) A method of male contraception consisting essentially of the step of: administering to a non-sterile male subject a predetermined amount of a non-5 α -reducible androgen which is sufficient to render said male subject reversibly sterile for a predetermined period of time.

3. (previously presented) The method of claims 1 or 2 wherein said androgen is MENT and its pharmaceutically acceptable salts.

4. (currently amended) The method of claim 3 wherein said predetermined period of time is at least 1 day and said predetermined amount of MENT ~~or~~ and pharmaceutically acceptable salts thereof is an amount which is sufficient to render said male subject reversibly sterile each day over said predetermined period.

5. (currently amended) The method of claim 4 wherein said predetermined period of time is a plurality of days and said predetermined amount of MENT ~~or~~ and pharmaceutically acceptable salts thereof is an amount which is sufficient to render said male subject reversibly sterile each day over said predetermined period.

6. (currently amended) The method of claim 5 wherein said predetermined period of time is at least 7 days and said predetermined amount of MENT ~~or~~—and pharmaceutically acceptable salts thereof is an amount which is sufficient to render said male subject reversibly sterile each day over said predetermined period.

7. (currently amended) The method of claim 5 wherein said predetermined period of time is at least 30 days and said predetermined amount of MENT ~~or~~—and pharmaceutically acceptable salts thereof is an amount which is sufficient to render said male subject reversibly sterile each day over said predetermined period.

8. (currently amended) The method of claim 5 wherein said predetermined period of time is at least 180 days and said predetermined amount of MENT ~~or~~—and pharmaceutically acceptable salts thereof is an amount which is sufficient to render said male subject reversibly sterile each day over said predetermined period.

9. (previously presented) The method of claim 3 wherein said predetermined amount of MENT or a pharmaceutically acceptable salt thereof, is a bioavailable amount ranging from between about 200 to about 2000 micrograms/day.

10. (previously presented) The method of claim 9 wherein said predetermined amount of MENT or a pharmaceutically acceptable salt thereof, is a bioavailable amount ranging from between about 400 to about 1500 micrograms/day.

11. (previously presented) The method of claim 10 wherein said predetermined amount of MENT or a pharmaceutically acceptable salt thereof, is a bioavailable amount ranging from between about 500 to about 1000 micrograms/day.

12. (currently amended) The method of claim 11 wherein said predetermined amount of MENT or a pharmaceutically acceptable salt thereof, is a bioavailable amount ~~ranging~~ provides—providing mean steady state serum levels of 1.0 nmol/Liter/day or greater.

13. (previously presented) The method of claim 1 wherein said predetermined amount of a non-5 α -reducible androgen is sufficient to provide said male subject with blood levels of LH and FSH of 2.0 IU/L or less and testosterone of 5 nmol/liter or less.

14. (previously presented) The method of claim 13 wherein said predetermined amount of a non-5 α -reducible androgen is sufficient to provide said male subject with blood levels of LH and FSH of 1.5 IU/L or less and testosterone of 4 nmol/liter or less.

15. (previously presented) The method of claim 14 wherein said predetermined amount of a non-5 α -reducible androgen is sufficient to provide said male subject with blood levels of LH and FSH of 1.0 IU/L or less and testosterone of 3 nmol/liter or less.

16. (canceled).

17. (previously presented) The method of claims 1 or 2 wherein said predetermined amount of a non-5 α -reducible androgen is administered to said subject by injection.

18. (previously presented) The method of claims 1 or 2 wherein said predetermined amount of a non-5 α -reducible androgen is administered to said subject by implant.

19. (previously presented) The method of claims 1 or 2 wherein said predetermined amount of a non-5 α -reducible androgen is administered to said subject by topical application.

20. (previously presented) The method of claim 14 wherein said predetermined amount of a non-5 α -reducible androgen

is administered to said subject as a cream, lotion, gel or in a transdermal patch.

21. (original) The method of claims 1 or 2 wherein said predetermined amount of androgen is administered to said subject orally.

Claims 22-44 (canceled).